AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

The Effects of Intravenous Iron on Mobility in Elderly Patients Following Hip Fracture Surgery

RecruitingPhase 4Ages 65 Years - anyAllSoren Overgaard
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The primary aim of this clinical trial is to investigate the effects of intravenous iron on recovery in mobility compared to the pre-fracture level in patients with a hip fracture The main questions it aims to answer are: It is hypothesize that intravenous iron will enhance gains in mobility and hereby recovery of mobility, increase hemoglobin (Hgb), lower fatigue, have a positive effect on skeletal muscles in the weeks and months after administration. The primary objective is to compare the effect of a single dose of ferric derisomaltose (FDI) (20 mg/kg body weight) relative to placebo on patients' recovery of functional mobility, measured as the change from baseline in the New Mobility Score. Participants will: \- Receive either a single dose of intravenous FDI (20 mg/kg body weight) (and saline) or placebo (saline) at 1-5 days after surgery. This trial will be conducted at three

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. 65 years of age or older 2. Acute proximal femur fracture surgery 3. A hemoglobin measurement โ‰ค6.5 mmol/L (10.5 g/dL) on day 1 to 5 postoperatively 4. Independent prefracture indoor walking ability, indoor NMS โ‰ฅ 2 5. Ability to speak and understand Danish 6. Able to provide informed consent on the participants own behalf Exclusion Criteria: 1. Known allergy to intravenous iron 2. Residing permanently at a nursing home 3. Hematological conditions with a risk of iron overload e.g. haemochromatosis, hemosiderosis, or where alternative treatments are necessary e.g. haematological malignancies 4. Other contraindication to iron treatment, e.g. severe liver cirrhosis and hepatitis 5. Severe uncontrolled infection as assessed by the responsible clinician (e.g. bacteraemia or sepsis) 6. Plasma sodium levels below 125 or above 150 mmol/L on the day of inclusion 7. Renal replacement therapy 8. Severe dementia assessed by physician 9. Recent intravenous iron injection, 4 weeks prior to surgery 10. Patient declared terminally ill 11. Pathologic Fracture
๐Ÿ’Š

What it tests

  • Ferric Derisomaltose
  • Saline (NaCl 0,9 %) (placebo)
๐Ÿ“

Where

3 sites
Department of Orthopedic Surgery and Traumatology, Bispebjerg, Copenhagen University Hospital
Copenhagen NV, Denmark
Department of Orthopedic Surgery and Traumatology, Herlev, Copenhagen University Hospital
Herlev, Denmark
Department of Orthopaedic Surgery, Odense and Svendborg University Hospital
Odense C, Denmark
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy